Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DISSECTING THE EPIGENOME AND MICROENVIRONMENT TO UNDERSTAND IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER (DEMETER PROJECT)

NCT07374809 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT07374809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07374809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DISSECTING THE EPIGENOME AND MICROENVIRONMENT TO UNDERSTAND IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER (DEMETER PROJECT)
Lead sponsor
European Institute of Oncology
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 21, 2026
Completion date
November 30, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dmmr cancer, endometrial carcinoma (ec), pmmr